Benchmark Upgrades Repligen to Buy, Announces $185 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 56.8%

Neg 0% Neu 56.8% Pos 0%

Benchmark analyst Robert Wasserman upgrades Repligen (NASDAQ:RGEN) from Hold to Buy and announces $185 price target.

Comments

No comments yet. Be the first!